Carbamylated erythropoietin does not alleviate signs of dystrophy in mdx mice

Muscle and Nerve

Volumn 43, Issue 1, 2011, Pages 88-93

  Wu, Melissa P ^a   Gussoni, Emanuela ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

C EPO; Dystrophy; Fibrosis; Mdx; Muscular

Indexed keywords

CARBAMYLATED ERYTHROPOIETIN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; HISTOLOGY; MOUSE; MUSCLE EXAMINATION; NONHUMAN; PRIORITY JOURNAL; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE; DIAPHRAGM; GASTROCNEMIUS MUSCLE; HISTOPATHOLOGY; MUSCULAR DYSTROPHY;

ANIMALS; CELL PROLIFERATION; CREATINE KINASE; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; FEMALE; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MYOBLASTS; NEUROPROTECTIVE AGENTS; TREATMENT FAILURE;

EID: 78650481675     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21785     Document Type: Article

References (48)

1. Monaco AP, Kunkel LM. Cloning of the Duchenne/Becker muscular dystrophy locus. Adv Hum Genet 1988;17:61-98.
2. Bulfield G, Siller WG, Wight PA, Moore KJ. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 1984;81:1189-1192. (Pubitemid 14171480)
3. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987;51:919-928.
4. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 1989;244:1578-1580.
5. Ryder-Cook AS, Sicinski P, Thomas K, Davies KE, Worton RG, Barnard EA, et al. Localization of the mdx mutation within the mouse dystrophin gene. EMBO J 1988;7:3017-3021.
6. Cavanna JS, Coulton G, Morgan JE, Brockdorff N, Forrest SM, Davies KE, et al. Molecular and genetic mapping of the mouse mdx locus. Genomics 1988;3:337-341.
7. Spencer MJ, Montecino-Rodriguez E, Dorshkind K, Tidball JG. Helper (CD4 (+)) and cytotoxic (CD8 (+)) T cells promote the pathology of dystrophin-deficient muscle. Clin Immunol 2001;98:235-243.
8. Spencer MJ, Tidball JG. Do immune cells promote the pathology of dystrophin-deficient myopathies? Neuromuscul Disord 2001;11:556-564.
9. Karpati G, Carpenter S, Prescott S. Small-caliber skeletal muscle fibers do not suffer necrosis in mdx mouse dystrophy. Muscle Nerve 1988;11:795-803.
10. Tanabe Y, Esaki K, Nomura T. Skeletal muscle pathology in X chromosome-linked muscular dystrophy (mdx) mouse. Acta Neuropathol 1986;69:91-95.
11. Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B, et al. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 1991;352:536-539.
12. Nichol CJ. Serum creatine phosphokinase measurements in muscular dystrophy studies. Clin Chim Acta 1965;11:404-407.
13. Pearce JM, Pennington RJ, Walton JN. Serum enzyme studies in muscle disease. II. Serum creatine kinase activity in muscular dystrophy and in other myopathic and neuropathic disorders. J Neurol Neurosurg Psychiatry 1964;27:96-99.
14. Fowler WM Jr. Diagnostic and prognostic significance of serum enzymes. I. Muscular dystrophy. Arch Phys Med Rehabil 1964;45:117-124.
15. Swaiman KF, Sandler B. The use of serum creatine phosphokinase and other serum enzymes in the diagnosis of progressive muscular dystrophy. J Pediatr 1963;63:1116-1119.
16. Nelson SF, Crosbie RH, Miceli MC, Spencer MJ. Emerging genetic therapies to treat Duchenne muscular dystrophy. Curr Opin Neurol 2009;22:532-538.
17. Muir LA, Chamberlain JS. Emerging strategies for cell and gene therapy of the muscular dystrophies. Expert Rev Mol Med 2009;11: e18.
18. Peault B, Rudnicki M, Torrente Y, Cossu G, Tremblay JP, Partridge T, et al. Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol Ther 2007;15:867-877. (Pubitemid 46621645)
19. Heemskerk H, de Winter CL, van Ommen GJ, van Deutekom JC, Aartsma-Rus A. Development of antisense-mediated exon skipping as a treatment for Duchenne muscular dystrophy. Ann NY Acad Sci 2009;1175:71-79.
20. Wood MJ, Gait MJ, Yin H. RNA-targeted splice-correction therapy for neuromuscular disease. Brain 2010;133:957-972.
21. Patel K, Macharia R, Amthor H. Molecular mechanisms involving IGF-1 and myostatin to induce muscle hypertrophy as a therapeutic strategy for Duchenne muscular dystrophy. Acta Myol 2005;24:230-241.
22. Khurana TS, Davies KE. Pharmacological strategies for muscular dystrophy. Nat Rev Drug Discov 2003;2:379-390.
23. Hanazono Y, Sasaki K, Nitta H, Yazaki Y, Hirai H. Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF receptor. Biochem Biophys Res Commun 1995;208:1060-1066.
24. Jubinsky PT, Krijanovski OI, Nathan DG, Tavernier J, Sieff CA. The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood 1997;90:1867-1873.
25. Ghezzi P, Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ 2004;11(suppl 1): S37-44.
26. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004;101:14907-14912.
27. Joyeux-Faure M, Godin-Ribuot D, Ribuot C. Erythropoietin and myocardial protection: what's new? Fundam Clin Pharmacol 2005;19:439-446.
28. Ogilvie M, Yu X, Nicolas-Metral V, Pulido SM, Liu C, Ruegg UT, et al. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem 2000;275:39754-39761.
29. Davenport A, King RF, Ironside JW, Will EJ, Davison AM. The effect of treatment with recombinant human erythropoietin on the histological appearance and glycogen content of skeletal muscle in patients with chronic renal failure treated by regular hospital haemodialysis. Nephron 1993;64:89-94. (Pubitemid 23117175)
30. Vaziri ND. Cardiovascular effects of erythropoietin and anemia correction. Curr Opin Nephrol Hypertens 2001;10:633-637.
31. Kao RL, Xenocostas A, Rui TR, Yu P, Huang W, Rose J, et al. Erythropoietin improves skeletal muscle microcirculation and tissue bioenergetics in a mouse sepsis model. Crit Care 2007;11: R58.
32. Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007;2:1274-1282.
33. Rosner MH, Bolton WK. The mortality risk associated with higher hemoglobin: is the therapy to blame? Kidney Int 2008;74:695-697.
34. Heinicke K, Baum O, Ogunshola OO, Vogel J, Stallmach T, Wolfer DP, et al. Excessive erythrocytosis in adult mice overexpressing erythropoietin leads to hepatic, renal, neuronal, and muscular degeneration. Am J Physiol Regul Integr Comp Physiol 2006;291: R947-956.
35. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239-242.
36. Mennini T, De Paola M, Bigini P, Mastrotto C, Fumagalli E, Barbera S, et al. Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Mol Med 2006;12:153-160.
37. Villa P, van Beek J, Larsen AK, Gerwien J, Christensen S, Cerami A, et al. Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J Cereb Blood Flow Metab 2007;27:552-563.
38. Savino C, Pedotti R, Baggi F, Ubiali F, Gallo B, Nava S, et al. Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J Neuroimmunol 2006;172:27-37.
39. Srisawat N, Manotham K, Eiam-Ong S, Katavetin P, Praditpornsilpa K, Eiam-Ong S. Erythropoietin and its non-erythropoietic derivative: do they ameliorate renal tubulointerstitial injury in ureteral obstruction? Int J Urol 2008;15:1011-1017.
40. Bianchi R, Brines M, Lauria G, Savino C, Gilardini A, Nicolini G, et al. Protective effect of erythropoietin and its carbamylated derivative in experimental cisplatin peripheral neurotoxicity. Clin Cancer Res 2006;12:2607-2612.
41. Fiordaliso F, Chimenti S, Staszewsky L, Bai A, Carlo E, Cuccovillo I, et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci USA 2005;102:2046-2051.
42. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002;420:418-421.
43. Scoppetta C, Grassi F. Erythropoietin: a new tool for muscle disorders? Med Hypotheses 2004;63:73-75.
44. Lapchak PA. Carbamylated erythropoietin to treat neuronal injury: new development strategies. Expert Opin Invest Drugs 2008;17:1175-1186.
45. Xu X, Cao Z, Cao B, Li J, Guo L, Que L, et al. Carbamylated erythropoietin protects the myocardium from acute ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Surgery 2009;146:506-514.
46. Glass DJ. Molecular mechanisms modulating muscle mass. Trends Mol Med 2003;9:344-350.
47. Lai KM, Gonzalez M, Poueymirou WT, Kline WO, Na E, Zlotchenko E, et al. Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy. Mol Cell Biol 2004;24:9295-9304.
48. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-475. (Pubitemid 34441737)